Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial
Cephalalgia · 2023
DOI: 10.1177/03331024231190296 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2023. Verfasst von Richard B Lipton und 9 weiteren Autor:innen. Beteiligte Einrichtung: Albert Einstein College of Medicine, Bronx, NY, USA. Hauptthemen laut MEDLINE: Quality of Life, Piperidines, Pyridines, Pyrroles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Allergan.
Abstract (Originalsprache)
Background
Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine.
Methods
In this 52-week, multicenter, randomized, open-label trial, adults with 4–14 monthly migraine days received atogepant 60 mg once-daily or standard care. Health outcome endpoints collected from participants randomized to atogepant included change from baseline in Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1) Role Function-Restrictive (RFR), Role Function-Preventive (RFP) and Emotional Function (EF) domain scores, change in Activity Impairment in Migraine-Diary (AIM-D) Performance of Daily Activities (PDA) and Physical Impairment (PI) domain scores, and change in Headache Impact Test-6 (HIT-6) total score.
Results
Of 744 randomized participants, 521 received atogepant 60 mg in the modified intent-to-treat population. Least-squares mean changes from baseline in MSQ-RFR score were 30.02 (95% confidence interval = 28.16–31.87) at week 12 and 34.70 (95% confidence interval = 32.74–36.66) at week 52. Improvements were also observed in other MSQ domains, AIM-D PDA, PI and HIT-6 total scores. A ≥5-point improvement from baseline in HIT-6 score was observed in 59.9% of participants at week 4 and 80.8% of participants at week 52.
Conclusion
Over 52 weeks, atogepant 60 mg once-daily was associated with sustained improvements in quality of life and reductions in activity impairment and headache impact. Trial Registration: NCT03700320
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Albert Einstein College of Medicine, Bronx, NY, USA.
- Mayo Clinic, Scottsdale, AZ, USA.
- Dent Neurologic Institute, Buffalo, NY, USA.
- AbbVie, Madison, NJ, USA.
- AbbVie, Irvine, CA, USA.
- Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Denmark.
ORCID-Profile: Richard B Lipton, Laszlo Mechtler
Förderung
- Allergan
Zitieren
APA
Lipton, R. B., Halker Singh, R. B., Mechtler, L., McVige, J., Ma, J., Yu, S. Y., Stokes, J., Dabruzzo, B., Gandhi, P., & Ashina, M. (2023). Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial. Cephalalgia. https://doi.org/10.1177/03331024231190296
Vancouver
Lipton RB, Halker Singh RB, Mechtler L, McVige J, Ma J, Yu SY, et al. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial. Cephalalgia. 2023. doi:10.1177/03331024231190296
BibTeX
@article{Lipton2023,
author = {Lipton, Richard B and Halker Singh, Rashmi B and Mechtler, Laszlo and McVige, Jennifer and Ma, Julia and Yu, Sung Yun and Stokes, Jonathan and Dabruzzo, Brett and Gandhi, Pranav and Ashina, Messoud},
title = {Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial},
journal = {Cephalalgia},
year = {2023},
doi = {10.1177/03331024231190296}
}
EUVIMED